Which has better valuation and earnings, SANA or CELC?

Celcuity is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sana Biotechnology N/A N/A -$244.17M -$0.76 N/A Celcuity N/A N/A -$177.04M -$4.30 N/A

Is SANA or CELC more profitable?

Sana Biotechnology's return on equity of -103.02% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Sana Biotechnology N/A -103.02% -39.16% Celcuity N/A -350.78% -41.54%

Does the media refer more to SANA or CELC?

In the previous week, Sana Biotechnology had 2 more articles in the media than Celcuity. MarketBeat recorded 12 mentions for Sana Biotechnology and 10 mentions for Celcuity. Celcuity's average media sentiment score of 1.20 beat Sana Biotechnology's score of 0.85 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, SANA or ELVN?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sana Biotechnology N/A N/A -$244.17M -$0.76 N/A Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A

Is SANA or ELVN more profitable?

Enliven Therapeutics' return on equity of -18.55% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Sana Biotechnology N/A -103.02% -39.16% Enliven Therapeutics N/A -18.55% -18.09%

Does the media refer more to SANA or ELVN?

In the previous week, Sana Biotechnology had 1 more articles in the media than Enliven Therapeutics. MarketBeat recorded 12 mentions for Sana Biotechnology and 11 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.76 beat Sana Biotechnology's score of 0.85 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is AMLX or SANA more profitable?

Amylyx Pharmaceuticals' return on equity of -52.92% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Amylyx Pharmaceuticals N/A -52.92% -48.53% Sana Biotechnology N/A -103.02% -39.16%

Does the media refer more to AMLX or SANA?

In the previous week, Amylyx Pharmaceuticals and Amylyx Pharmaceuticals both had 12 articles in the media. Amylyx Pharmaceuticals' average media sentiment score of 1.45 beat Sana Biotechnology's score of 0.85 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sana Biotechnology 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SANA or RLAY more profitable?

Relay Therapeutics' return on equity of -42.27% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Sana Biotechnology N/A -103.02% -39.16% Relay Therapeutics N/A -42.27% -38.67%

Does the media prefer SANA or RLAY?

In the previous week, Relay Therapeutics had 7 more articles in the media than Sana Biotechnology. MarketBeat recorded 19 mentions for Relay Therapeutics and 12 mentions for Sana Biotechnology. Relay Therapeutics' average media sentiment score of 1.09 beat Sana Biotechnology's score of 0.85 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 14 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SANA or LEGN?

In the previous week, Sana Biotechnology had 10 more articles in the media than Legend Biotech. MarketBeat recorded 12 mentions for Sana Biotechnology and 2 mentions for Legend Biotech. Sana Biotechnology's average media sentiment score of 0.85 beat Legend Biotech's score of 0.62 indicating that Sana Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sana Biotechnology (SANA) Competitors

$3.93 -0.16 (-3.91%)

As of 08/28/2026 04:00 PM Eastern

Compare

SANA vs. CELC, ELVN, AMLX, RLAY, and LEGN

Should you buy Sana Biotechnology stock or one of its competitors? Sana Biotechnology's main competitors and comparable companies include Celcuity (CELC), Enliven Therapeutics (ELVN), Amylyx Pharmaceuticals (AMLX), Relay Therapeutics (RLAY), and Legend Biotech (LEGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sana Biotechnology compare to Celcuity?

Sana Biotechnology (NASDAQ:SANA) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Sana Biotechnology currently has a consensus target price of $9.33, suggesting a potential upside of 137.49%. Celcuity has a consensus target price of $154.55, suggesting a potential upside of 74.75%. Given Sana Biotechnology's higher probable upside, equities research analysts plainly believe Sana Biotechnology is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, Sana Biotechnology had 2 more articles in the media than Celcuity. MarketBeat recorded 12 mentions for Sana Biotechnology and 10 mentions for Celcuity. Celcuity's average media sentiment score of 1.20 beat Sana Biotechnology's score of 0.85 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Celcuity is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

Sana Biotechnology has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market.

Sana Biotechnology's return on equity of -103.02% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
Celcuity	N/A	-350.78%	-41.54%

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 63.3% of Celcuity shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by insiders. Comparatively, 13.3% of Celcuity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Sana Biotechnology beats Celcuity on 10 of the 14 factors compared between the two stocks.

How does Sana Biotechnology compare to Enliven Therapeutics?

Sana Biotechnology (NASDAQ:SANA) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Sana Biotechnology presently has a consensus price target of $9.33, suggesting a potential upside of 137.49%. Enliven Therapeutics has a consensus price target of $75.00, suggesting a potential upside of 29.62%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, research analysts clearly believe Sana Biotechnology is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Enliven Therapeutics' return on equity of -18.55% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
Enliven Therapeutics	N/A	-18.55%	-18.09%

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by company insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Sana Biotechnology has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

In the previous week, Sana Biotechnology had 1 more articles in the media than Enliven Therapeutics. MarketBeat recorded 12 mentions for Sana Biotechnology and 11 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.76 beat Sana Biotechnology's score of 0.85 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Sana Biotechnology beats Enliven Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Sana Biotechnology compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Sana Biotechnology (NASDAQ:SANA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Amylyx Pharmaceuticals and Amylyx Pharmaceuticals both had 12 articles in the media. Amylyx Pharmaceuticals' average media sentiment score of 1.45 beat Sana Biotechnology's score of 0.85 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amylyx Pharmaceuticals currently has a consensus target price of $36.50, suggesting a potential upside of 5.07%. Sana Biotechnology has a consensus target price of $9.33, suggesting a potential upside of 137.49%. Given Sana Biotechnology's higher possible upside, analysts clearly believe Sana Biotechnology is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Amylyx Pharmaceuticals has a beta of -0.21, indicating that its stock price is 121% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market.

Amylyx Pharmaceuticals has higher revenue and earnings than Sana Biotechnology. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	44.30	-$144.74M	-$1.43	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

Amylyx Pharmaceuticals' return on equity of -52.92% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
Sana Biotechnology	N/A	-103.02%	-39.16%

Summary

Amylyx Pharmaceuticals beats Sana Biotechnology on 8 of the 14 factors compared between the two stocks.

How does Sana Biotechnology compare to Relay Therapeutics?

Sana Biotechnology (NASDAQ:SANA) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

Sana Biotechnology has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market.

Sana Biotechnology presently has a consensus price target of $9.33, suggesting a potential upside of 137.49%. Relay Therapeutics has a consensus price target of $25.92, suggesting a potential upside of 38.07%. Given Sana Biotechnology's higher probable upside, equities analysts clearly believe Sana Biotechnology is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Sana Biotechnology has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A
Relay Therapeutics	$10.35M	397.42	-$276.48M	-$1.57	N/A

In the previous week, Relay Therapeutics had 7 more articles in the media than Sana Biotechnology. MarketBeat recorded 19 mentions for Relay Therapeutics and 12 mentions for Sana Biotechnology. Relay Therapeutics' average media sentiment score of 1.09 beat Sana Biotechnology's score of 0.85 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	14 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Relay Therapeutics' return on equity of -42.27% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
Relay Therapeutics	N/A	-42.27%	-38.67%

Summary

Relay Therapeutics beats Sana Biotechnology on 9 of the 15 factors compared between the two stocks.

How does Sana Biotechnology compare to Legend Biotech?

Sana Biotechnology (NASDAQ:SANA) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Sana Biotechnology has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Sana Biotechnology has a net margin of 0.00% compared to Legend Biotech's net margin of -7.21%. Legend Biotech's return on equity of -8.71% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
Legend Biotech	-7.21%	-8.71%	-5.40%

Sana Biotechnology has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A
Legend Biotech	$1.27B	2.90	-$296.80M	-$0.25	N/A

Sana Biotechnology currently has a consensus target price of $9.33, suggesting a potential upside of 137.49%. Legend Biotech has a consensus target price of $52.29, suggesting a potential upside of 163.01%. Given Legend Biotech's higher probable upside, analysts plainly believe Legend Biotech is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47

In the previous week, Sana Biotechnology had 10 more articles in the media than Legend Biotech. MarketBeat recorded 12 mentions for Sana Biotechnology and 2 mentions for Legend Biotech. Sana Biotechnology's average media sentiment score of 0.85 beat Legend Biotech's score of 0.62 indicating that Sana Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sana Biotechnology beats Legend Biotech on 10 of the 16 factors compared between the two stocks.

Get Sana Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SANA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SANA vs. The Competition

Export

Metric	Sana Biotechnology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.18B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-5.17	11.62	273.16	25.45
Price / Sales	N/A	1,295.87	605.06	76.64
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	7.56	16.53	12.98	6.14
Net Income	-$244.17M	-$22.80M	$3.48B	$348.86M
7 Day Performance	0.51%	-0.31%	0.13%	-0.80%
1 Month Performance	20.92%	9.80%	7.08%	4.13%
1 Year Performance	28.43%	55.66%	24.67%	15.17%

Sana Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SANA Sana Biotechnology	2.4137 of 5 stars	$3.93 -3.9%	$9.33 +137.5%	+28.4%	$1.18B	N/A	N/A	380	News Coverage
CELC Celcuity	2.7597 of 5 stars	$90.79 -2.9%	$154.55 +70.2%	+72.6%	$4.58B	N/A	N/A	40	News Coverage Positive News
ELVN Enliven Therapeutics	3.0647 of 5 stars	$61.15 +2.2%	$75.00 +22.6%	+185.4%	$4.38B	N/A	N/A	50	News Coverage
AMLX Amylyx Pharmaceuticals	2.3264 of 5 stars	$38.15 -1.3%	$36.25 -5.0%	+270.4%	$4.31B	N/A	N/A	200	Positive News Analyst Forecast
RLAY Relay Therapeutics	2.7253 of 5 stars	$19.76 +1.6%	$25.92 +31.2%	+422.8%	$4.26B	$15.35M	N/A	330	News Coverage Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SANA) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sana Biotechnology (SANA) Competitors

SANA vs. CELC, ELVN, AMLX, RLAY, and LEGN

How does Sana Biotechnology compare to Celcuity?

Summary

How does Sana Biotechnology compare to Enliven Therapeutics?

Summary

How does Sana Biotechnology compare to Amylyx Pharmaceuticals?

Summary

How does Sana Biotechnology compare to Relay Therapeutics?

Summary

How does Sana Biotechnology compare to Legend Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA vs. The Competition

Sana Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sana Biotechnology (SANA) Competitors

SANA vs. CELC, ELVN, AMLX, RLAY, and LEGN

How does Sana Biotechnology compare to Celcuity?

Do analysts prefer SANA or CELC?

Does the media refer more to SANA or CELC?

Which has better valuation and earnings, SANA or CELC?

Which has more volatility & risk, SANA or CELC?

Is SANA or CELC more profitable?

Do institutionals & insiders have more ownership in SANA or CELC?

Summary

How does Sana Biotechnology compare to Enliven Therapeutics?

Which has higher earnings & valuation, SANA or ELVN?

Do analysts prefer SANA or ELVN?

Is SANA or ELVN more profitable?

Do institutionals and insiders have more ownership in SANA or ELVN?

Which has more volatility and risk, SANA or ELVN?

Does the media refer more to SANA or ELVN?

Summary

How does Sana Biotechnology compare to Amylyx Pharmaceuticals?

Do insiders and institutionals have more ownership in AMLX or SANA?

Does the media refer more to AMLX or SANA?

Do analysts recommend AMLX or SANA?

Which has more risk and volatility, AMLX or SANA?

Which has higher valuation and earnings, AMLX or SANA?

Is AMLX or SANA more profitable?

Summary

How does Sana Biotechnology compare to Relay Therapeutics?

Which has more volatility & risk, SANA or RLAY?

Do analysts prefer SANA or RLAY?

Which has stronger earnings and valuation, SANA or RLAY?

Does the media prefer SANA or RLAY?

Do insiders & institutionals have more ownership in SANA or RLAY?

Is SANA or RLAY more profitable?

Summary

How does Sana Biotechnology compare to Legend Biotech?

Which has more volatility & risk, SANA or LEGN?

Do insiders & institutionals hold more shares of SANA or LEGN?

Is SANA or LEGN more profitable?

Which has better earnings and valuation, SANA or LEGN?

Do analysts rate SANA or LEGN?

Does the media refer more to SANA or LEGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA vs. The Competition

Sana Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools